Relationship between expression of blood circulating lncRNA: LRRC75A-AS1, clinical characteristics and prognosis of chronic heart failure patients

Introduction: A complex interplay of genetics and multiple biological mechanisms contributes not only to chronic heart failure (CHF) progression and an unfavorable prognosis, but also makes biomarker selection difficult. Discovery of novel molecular markers, such as lncRNAs, has provided a new approach to biomarker study, including for CHF. Aim of the research: In this study, we focused on blood circulating LRRC75A-AS1 as a novel prospective biomarker reflecting the clinical image and prognosis of CHF patients. Material and methods: The lncRNA expression was examined in plasma samples of 108 newly diagnosed CHF patients and correlated with clinical outcomes. Results: Low expression of LRRC75A-AS1 was associated with a greater inflammatory response reflected by higher plasma concentrations of C-reactive protein, interleukin-6 and tumor necrosis factor a. Patients with low lncRNA expression had lower serum albumin concentration and they were more frequently classified as NYHA grade III or IV, had PASP >= 36 mm Hg and more often demonstrated presence of exertional dyspnea. The Cox regression model selected downexpression of LRRC75A-AS1 as an independent prognostic factor related to poor survival of CHF (HR = 2.17). Conclusions: Blood circulating LRRC75A-AS1 seems to be an attractive biomarker supporting clinical assessment of CHF patients. Expression of the lncRNA reflects the extent of the CHF symptoms and severity of the systemic inflammatory response, which can be useful for selection of patients with an unfavorable disease course and higher risk of death.